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tion in promoting the survival of dopamine (DA) neurons.
Several studies indicate that increasing GDNF levels may be
beneficial for the treatment of Parkinson’s disease (PD) by
reducing neurodegeneration of DA neurons. Despite a plethora
of preclinical studies showing GDNF efficacy in PD animal
models, its application in humans remains questionable for
its poor efficacy and side effects due to its uncontrolled, ectopic
expression. Here we took advantage of SINEUPs, a new class of
antisense long non-coding RNA, that promote translation of
partially overlapping sense protein-coding mRNAs with no ef-
fects on their mRNA levels. By synthesizing a SINEUP target-
ing Gdnf mRNA, we were able to increase endogenous GDNF
protein levels by about 2-fold. Adeno-associated virus (AAV)
9-mediated delivery in the striatum of wild-type (WT) mice
led to an increase of endogenous GDNF protein for at least
6 months and the potentiation of the DA system’s functions
while showing no side effects. Furthermore, SINEUP-GDNF
was able to ameliorate motor deficits and neurodegeneration
of DA neurons in a PD neurochemical mouse model. Our
data indicate that SINEUP-GDNF could represent a new strat-
egy to increase endogenous GDNF protein levels in a more
physiological manner for therapeutic treatments of PD.Received 25 March 2019; accepted 12 August 2019;
https://doi.org/10.1016/j.ymthe.2019.08.005.
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Parkinson’s Disease (PD) is one of the most common neurodegener-
ative disorders, and it is caused by loss of the dopamine (DA) neurons
of the substantia nigra pars compacta (SNpc). It manifests its symp-
tomatology mainly as motor-related deficits, such as rigidity, tremor,
and bradykinesia.1 Although familial PD (about 5% of the total cases)
has been important to unveil the molecular pathways involved in neu-
rodegeneration, most of the PD patients are sporadic.2 Currently, no
treatments are available that can slow or arrest neurodegeneration.
The DA precursor L-DOPA is the gold standard for symptomaticMolec
This is an open access article under the CC BY-Ntreatments, although over time it may lead to several side effects
and resistance.3
Glial cell-derived neurotrophic factor (GDNF) is the most potent
neurotrophic factor for DA neurons with great potentiality for clinical
application.4,5 GDNF can protect DA cells and promotes their sur-
vival from toxic insults in vitro and in vivo in mice, rats, and non-hu-
man primates.6–8 However, clinical trials with recombinant GDNF
showed an inconsistency of results, due to the poor spreading of
GDNF within the parenchyma and to the unsustainable side effects
caused by the high doses of GDNF administered.9–11 Similarly,
GDNF expression through viral vectors that showed efficacy in PD
animal models may result in uncontrolled, ectopic GDNF overexpres-
sion. Therefore, GDNF may be the right candidate for PD therapy,
provided that a more specific and physiological expression is achieved
to increase its efficacy and safety profile in vivo. In this context, a dele-
tion in the 30 UTR of the GDNF gene in a transgenic mouse line led to
an increase of 2-fold of endogenous GDNF protein levels.12 This was
sufficient to induce alterations in the DA system and neuroprotection
similar to what was seen with a large overexpression of GDNF, but
without the side effects. These data corroborate the hypothesis that
a moderate increase in endogenous GDNF could be beneficial for PD.
We have previously identified antisense (AS) Uchl1 as a long non-
coding RNA (lncRNA) antisense tomouseUchl1/Park5 that increases
UchL1 protein synthesis at the post-transcriptional level.13 AS Uchl1
is the representative member of a new functional class of natural and
synthetic lncRNAs, named SINEUPs, that promote translation ofular Therapy Vol. 27 No 12 December 2019 ª 2019 The Authors. 1
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. miniSINEUP-GDNF RNA Increases Selectively GDNF Protein Expression In Vitro
(A) Schematic representation ofminiSINEUP-GDNF structure, with the SINEUP BD overlapping the 50 UTR of theGdnfmRNA. (B and C) Effect ofminiSINEUP-GDNFRNA on
endogenous GDNF protein levels in two cell lines, the Neuro2a (B) and the C8-D1A astrocytes (C) (F2, 12 = 8.09, p < 0.001, n = 5 for Neuro2a; and F2, 9 = 15.69, p < 0.01, n = 4
for astrocytes). miniSINEUP-GDNF transfected in cells increases GDNF proteins levels without altering Gdnf mRNA levels. Both miniSINEUP RNA with two different BD
(40/+4 and the14/+4, respectively) were expressed in transfected cells, but not in CTRL cells. (D)miniSINEUP-GDNF increases extracellular GDNF secreted by cells, as
(legend continued on next page)
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their mRNA levels.14 SINEUPs’ activity depends on the combination
of two domains: the overlapping region or binding domain (BD),
which dictates SINEUP specificity, and the embedded inverted
SINEB2 element, which acts as the effector domain (ED) controlling
the enhancement of mRNA translation. Their modular structure can
be employed to artificially engineer their BD and design synthetic
SINEUPs to specifically enhance translation of virtually any target
gene of interest. miniSINEUP RNAs are exclusively composed by
ED and BD sequences.
Synthetic SINEUPs and miniSINEUPs have been proven effective
with a number of targets, including GFP, FLAG-tagged proteins,
and secreted recombinant antibodies and cytokines, thus showing
SINEUP technology is scalable.15–17 Furthermore, SINEUPs can act
on endogenous mRNAs in vitro and in vivo. In a Medaka fish
model of microphthalmia with linear skin lesions and in a cellular
model of Friedreich ataxia, SINEUPs increased endogenous protein
levels of, respectively, Cox7b and frataxin, restoring eye development
in vivo and physiological mitochondria activity in patients’ cells.18
These results suggest the use of SINEUP technology in treating
haploinsufficiencies where a single functional allele is not sufficient
to encode for physiological amounts of the protein. In a parallel strat-
egy, SINEUPs may be used to increase the expression of neuroprotec-
tive agents to compensate for a disease phenotype.
Here we have designed and successfully tested miniSINEUP RNAs
specific for GDNF (miniSINEUP-GDNF) that selectively induced
GDNF protein levels in vitro. We then proved that these non-coding
RNAs are able to stably increase GDNF protein levels in the mouse
striatum. Finally, miniSINEUP-GDNF was able to ameliorate motor
deficits and DA neurodegeneration in mice unilaterally lesioned
with 6-hydroxy-dopamine (6-OHDA).
These results may pave the way to a new strategy for increasing
endogenous GDNF in PD therapy and to the establishment of a novel,
RNA-based therapeutic platform to address genetic and idiopathic
diseases.
RESULTS
miniSINEUP-GDNF RNA Selectively Increases GDNF Protein
Expression In Vitro
To design a specific SINEUP for endogenous Gdnf mRNA, we first
evaluated transcription start site (TSS) usage in cells and tissues rele-
vant for PD. We thus interrogated the FANTOM5 collection of Cap
Analysis of Gene Expression (CAGE) datasets, which represents the
widest catalog of annotated promoters and TSSs in mammalian sam-measured by an ELISA (n = 8). (E) Neuro2a cells were transfected with a pLVX-TetOne
treated with different concentrations of doxocycline for 24 h to evaluate the correlation b
miniSINEUP-GDNFRNA expression by doxocycline (F4, 29 = 3.45, p < 0.05) provokes an
miniSINEUP-GDNFwere studied. After a BLAST analysis, the protein andmRNA levels o
DAD1, CBX4, and LRRC14.miniSINEUP-GDNF did not alter protein or mRNA levels of th
***p < 0.001. Unpaired t test with Welch’s correction (D and F) or one-way ANOVA follples.19 By using the Zenbu Genome Browser Tool for data visualiza-
tion,20 we monitored TSS usage at the mouse GDNF locus and eval-
uated their expression in a variety of samples. The main TSS was close
to the first ATG, suggesting that the first two annotated isoforms
(NM_001301332.1 and NM_010275.3) were the most widely ex-
pressed (Figure S1).
Based on this TSS analysis, we designed two GDNF-specific
miniSINEUPs (miniSINEUP-GDNF) in antisense orientation to Gdnf
mRNA around the first AUG, following the rules of pairing at the sense
(S)/AS Uchl1 locus13 and for other natural and synthetic SINEUPs.14
While they presented the very same, original ED from the SINEB2
sequence of mouse AS Uchl1 RNA, two different BD sequences were
synthesized: a long one (40/+4) and a short one (14/+4), giving
rise to miniSINEUP-GDNFs of around 250 nt in length (Figure 1A).
To testminiSINEUP-GDNF efficacy, we took advantage of two mouse
cell lines that express endogenous GdnfmRNA,21 the neuroblastoma
Neuro2a and the astrocyte C8-D1A cell lines, verifying first that Gdnf
mRNA was present (Figure S2). SINEUP activity was evaluated by
measuring GDNF protein levels by western blot. Their post-tran-
scriptional control of target gene expression was monitored with
qRT-PCR. Both SINEUPs demonstrated a significant activity (Figures
1B and 1C), with the one with the short BD (14/+4) being the more
active (2.3- and 1.7-fold increases in Neuro2a and C8, respectively)
compared to the miniSINEUP-GDNF with the longest BD (1.9- and
1.4-fold increases in Neuro2a and C8, respectively). Both SINEUPs
did not show any effect at the transcriptional level, with no change
in Gdnf mRNA (Figures 1B and 1C).
Since GDNF is released outside cells and its secretion confers
neuroprotection of the DA terminals in the striatum, we measured
secreted GDNF protein levels in the medium of C8 astrocytes 2 days
from miniSINEUP-GDNF transfection. As shown in Figure 1D,
miniSINEUP-GDNF (14/+4) increased secreted GDNF protein
levels by about 40%. We then cloned miniSINEUP-GDNFs in a
pLVX-TetOne vector under the control of a doxocycline-inducible
promoter. miniSINEUP RNA levels reached a plateau at 250 ng/mL,
corresponding to its peak activity (Figure 1E).
SINEUP specificity is given by the BD nucleotide sequence that is
unique for the endogenous mRNA target. However, like other nucleic
acid-based techniques, off-targets cannot be excluded. Thus, we took
advantage of the BLAST to predict potential off-targets, aligning the
BD sequence to themousemRNA dataset. Three off-target candidates
showed the highest sequence similarity: Dad1 (homologous on the
30 UTR, 15 nt of similarity), Lrrc14 (homologous in the codingvector expressing the miniSINEUP-GDNF. After 24 h post-transfection, cells were
etween miniSINEUP RNA levels and GDNF protein expression. The induction of the
increase in GDNF protein levels (F4, 20 = 3.52, p < 0.05, n = 3). (F) Off-target effects of
f three possible off-targets were measured with western blot and qRT-PCR, namely,
ese potential off-targets (n = 3). Data represent means ± SEM. *p < 0.05, **p < 0.01,
owed by Dunnet’s multiple comparison test was used (B, C, and E).
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17 nt of similarity) (Table S1). As shown in Figure 1F, miniSINEUP-
GDNF did not alter the protein or mRNA levels of these genes,
proving the specificity of activity. To further demonstrate the on-
target effects of miniSINEUP-GDNF, we produced a miniSINEUP
lacking the BD (deltaBD-miniSINEUP-GDNF), to eliminate the
specificity for the endogenous Gdnf mRNA. Importantly, deltaBD-
miniSINEUP-GDNF had no effects on GDNF protein levels compared
to miniSINEUP-GDNF (Figure S3).
AAV9-Mediated Delivery of miniSINEUP-GDNF RNA Increases
Endogenous GDNF Expression in the Mouse Striatum
To test the functionality of theminiSINEUP-GDNF in vivo, we designed
anAAV9 vector to express SINEUPRNAunder the control of the cyto-
megalovirus (CMV) early enhancer/chicken beta-actin (CAG). Since
we couldn’t produce an AAV with two CAG promoters, we used
another ubiquitous promoter, the phosphoglycerate kinase (PGK), to
drive the expression of GFP, although its expected activity in astrocytes
is lower (Figure 2A).Using this vector,miniSINEUP-GDNFmaintained
its GDNF protein upregulation activity when tested in vitro in Neuro2a
and C8 astrocytes (Figure 2B). AAV9 vectors expressing miniSINEUP
RNA and the empty vector (CTRL) were produced and stereotaxically
injected into the dorsal striatum of adult C57BL/6J mice at the dose of
7.0  109 vector genomes (vg) per site of injection.
At 5 weeks post-infection, transgenes were widely expressed in the
majority of neurons of the dorsal striatum (Figure 2C). As expected,
PGK promoter wasmore effective in expressing GFP in neuronal than
in glial cells. We also noted some GFP-positive cells outside the area,
especially close to the ventricle, probably due to leaking of the virus.
Most importantly, miniSINEUP-GDNF increased GDNF protein
levels by about 80% (Figure 2D), an effect comparable to the one
seen in vitro in cell lines. RNA expression and SINEUP activity
were maintained up to 6 months after vector administration (Fig-
ure 2E). These results prove a stable expression of the transgene
and a continuous increase in endogenous GDNF protein levels.
Striatal GDNF Is Functionally Active In VivoWhen Synthesized
through a miniSINEUP-GDNF-Dependent Mechanism
Overexpression of GDNF in the striatum using viruses or the recom-
binant protein leads to several consequences, including an alteration
of the DA system’s functions.22 To test whether the increase in GDNF
protein levels achieved byminiSINEUP-GDNF RNA was functionally
relevant, we first injected mice with amphetamine, a DA reuptake in-
hibitor that stimulates locomotion. Interestingly, mice injected with
AAV9-miniSINEUP-GDNF were more sensitive to the stimulating ef-
fects of amphetamine (Figure 3A). We then used in vivomicrodialysis
to evaluate DA release in the striatum injected with miniSINEUP-
GDNF RNA. As shown in Figure 3B, DA basal levels were not
changed. However, when DA release was stimulated by the infusion
of potassium or amphetamine, mice with miniSINEUP-GDNF RNA
showed an enhanced DA release compared to CTRL animals (Figures
3C and 3D). This effect was likely due to an increase in DA storage in
the terminals, since we found an increase in DA total content in the4 Molecular Therapy Vol. 27 No 12 December 2019striatum of mice injected with AA9-miniSINEUP-GDNF, although a
higher number of DA cells’ terminals cannot be excluded (Figure 3E).
Uncontrolled ectopic expression of GDNF has led to several side ef-
fects in mice and in humans during clinical trials, including an in-
crease in basal locomotor activity and reduced body weight and
food intake.4,12 Here we showed that, 4 months after vector injection,
mice expressing miniSINEUP-GDNF RNA did not show any alter-
ation of locomotor parameters (Figure 3F), body weight (Figure 3G),
and food intake (Figure 3H). These results prove that the SINEUP-
mediated increase in GDNF occurs within a physiological range,
without triggering any deleterious effects in vivo.
miniSINEUP-GDNFRNARescuesNeurodegeneration andMotor
Phenotype in a PD Neurochemical Mouse Model
We then tested whether miniSINEUP-GDNF RNA was effective as a
neuroprotective agent in a PD neurochemical mouse model. To this
purpose, we stereotaxically injected AAV9-miniSINEUP-GDNF or
the CTRL virus into the striatum and induced 6-OHDA unilateral le-
sions 4 weeks later (Figure 4A). No evident signs of cortical damage
were induced by the two surgeries (Figure S4). 6-OHDA was able
to induce lesions of DA terminals, as previously shown by many
studies (Figure 4B).
At 6 weeks after the intoxication and 10 weeks after AAV injections,
we carried out a battery of behavioral tests. First, we performed the
cylinder test to assess the motor functionality of the forepaw,
since it is well known to be impaired in lesioned mice. Mice with
miniSINEUP-GDNF RNA showed an increase in contralateral
touches and a parallel decrease in ipsilateral touches, indicating a re-
covery of the forepaw that was under the control of the lesioned stria-
tum (Figure 4C). Then, we scored the mice for rotations, a sign of the
severity of the lesion. Both spontaneous rotations and those induced
by amphetamine were strongly reduced in mice with miniSINEUP-
GDNF RNA (Figure 4D), suggesting that miniSINEUP-GDNF was
able to reduce striatal neurodegeneration.
To verify this interpretation, we evaluated the quantity of DA
terminals in the lesioned striatum by measuring tyrosine hydroxylase
(TH) immunoreactivity. As shown in Figure 4E, mice injected with
miniSINEUP-GDNF showed an increase in TH staining and a reduc-
tion in the lesion induced by 6-OHDA intoxication. Furthermore,
mice with miniSINEUP-GDNF RNA showed an increase in TH-pos-
itive neurons in the SNpc with a recovery of the lesion of about 50%
(Figure 4F). To verify that the enhancement of GDNF protein levels
was present under pathological conditions, we carried out the very
same protocol of sequential viral injection and lesion with 6-OHDA
in another cohort of mice. As shown in Figure S5, mice injected
with AAV-miniSINEUP-GDNF presented higher levels of GDNF in
the striatum after 1 month from the time of lesion.
DISCUSSION
Nucleic acid-based therapy has been constantly developing in the last
years, with several drug candidates in clinical development for human
Figure 2. AAV9-Mediated Delivery Expression of miniSINEUP-GDNF RNA Increases Endogenous GDNF Expression in the Mouse Striatum
(A) Schematic representation of the modified AAV9 vector used to express the miniSINEUP-GDNF and GFP as a reporter. (B) AAV9 plasmid was transfected in Neuro2a
and astrocytes cell lines to test the expression ofminiSINEUP-GDNF. In both cell lines, GDNF protein levels were increased with no alteration ofGdnfmRNA levels (n = 3).
(C) AAV9 viral particles were stereotaxically injected in the right dorsal striatum of C57BL/6J mice and GFP expression was studied with a fluorescent microscope. Co-
localization immunofluorescence was performed to evaluate GFP expression. NeuN was used to stain neurons and GFAP to stain astrocytes. Most of the GFP (expressed
under PGK promoter) was present in neurons. Scale bars, 250 mm upper panel and 50 mm lower panels. (D) At 5 weeks after viral injection, striata were dissected and
GDNF protein levels were evaluated with western blot. Mice injected with the AAV9-miniSINEUP-GDNF showed an increase in GDNF protein levels (n = 6 for CTRL mice
and 7 forminiSINEUP-GDNFmice). (E, left panel) miniSINEUP RNA expression levels at different time points after viral injection. Mice injected with the virus were dissected
at 5, 20, and 30 weeks post-injection. SINEUP RNA was present at high levels up to 30 weeks (n = 7, 5, and 5 for each time point, respectively). (E, right panel) Effect of
AAV9-miniSINEUP-GDNF on GDNF protein levels at 30 weeks post-injection. Mice injected with AAV9-miniSINEUP-GDNF showed an increase in GDNF protein levels
(n = 6 for CTRL mice and 5 forminiSINEUP-GDNF mice). Data represent means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. Unpaired t test with Welch’s correction was
used.
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them are small interfering RNAs (siRNAs) and AS oligonucleotides
(ASOs). On the other hand, molecules able to increase the expression
of selected genes would be of great interest for the treatment of several
pathologies. To this purpose, transcriptional activating RNAs and
non-degradative ASOs have been recently used in vitro and in in vivo
disease models.24–26In this study, we demonstrate that SINEUPs, non-coding RNAs that
activate the translation of target mRNAs, can be used as a novel tool
for gene therapy. As a proof of concept, we designed a SINEUP tar-
geting endogenous Gdnf, and we proved that miniSINEUP-GDNF
RNA is effective in increasing GDNF protein levels in vivo and in
rescuing motor symptoms and neurodegeneration in a PD mouse
model.Molecular Therapy Vol. 27 No 12 December 2019 5
Figure 3. Striatal GDNF Is Functionally Active In Vivo When Synthesized
through a miniSINEUP-GDNF-Dependent Mechanism
(A) Mice, 4 months after AAV9-miniSINEUP-GDNF injection, were put in locomotor
chambers, injected with amphetamine at 2.5 mg/kg, and locomotor activity was
measured. Mice injected with AAV9-miniSINEUP-GDNF showed an increase in
locomotor activity (n = 12). (B) Extracellular DA release wasmeasured in the striatum
of mice injected with AAV9-miniSINEUP-GDNF, 4 months after injection. In vivo
microdialysis was performed to collect samples from the striatum, and DA was
measured using a high-performance liquid chromatography (HPLC) system. Basal
DA level was not changed between SINEUP and CTRL groups. After depolarization
of DA terminals by reverse microdialysis infusion of (C) potassium 120 nM or (D)
amphetamine 250 mM in the artificial cerebrospinal fluid (ACSF) solution, mice in-
jected with AAV9-miniSINEUP-GDNF showed an increase in DA extracellular levels
(treatment*mouse F8, 40 = 4.84, p < 0.001, n = 4). (E) Total striatal DA content was
measured from animals injected with AAV9-miniSINEUP-GDNF or CTRL virus. Mice
injected with AAV9-miniSINEUP-GDNF showed an increase in striatal DA total
content (n = 5). (F) Locomotor activity in mice injected with AAV9 vector was
measured at different time points after the injection. Total distance traveled by the
two groups of animals was evaluated for 3 months (n = 8). (G and H) Two different
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studies in rodents and non-human primates have been demonstrating
that increasing GDNF levels is beneficial for the survival of DA neu-
rons.4–7 However, clinical trials in humans with GDNF recombinant
protein did not give straightforward results, showing promising im-
provements but also a lack of efficacy and unsustainable side effects.
Major problems concern the large excess of the protein, way above
physiological levels, and its poor spreading in the tissue.9,11 Despite a
good efficacy in preclinical PD models, GDNF overexpression with
viral vectors, either lentivirus or AAV, has showed similar side effects
and limitations.4 This is possibly due to the uncontrolled overexpres-
sion of the transgene occurring above physiological levels. Side effects
and poor efficacy also can be caused by unspecific, ectopic expression
of the transgene in cells that normally do not present it. While it is
sometimes possible to drive transgene expression in the correct cells
with specific promoters, the repertory of human neuronal cell type-
specific promoters is very limited or they are often too large to be
included in a viral vector. GDNF expression in the striatum is restricted
to parvalbumin GABAergic interneurons, but the viral vectors used to
overexpress GDNF so far always contained ubiquitous promoters.
Here we show that both in vitro and in vivo miniSINEUP-GDNF
increases GDNF protein levels by about 2-fold. This is in line with
SINEUPs we and others developed, measuring upregulation of the
target protein in a range of 1.5- to 4-fold induction.14,16 As previously
shown in genetically modified mice,12 this moderate increase is suffi-
cient to physiologically modulate endogenous DA systems preventing
side effects.
The active miniSINEUP-GDNF has a BD of 18 nt that specifically
pairs with endogenous Gdnf mRNA isoforms. Therefore, SINEUPs
act only in cells that express the target mRNA. Since all nucleotide-
based approaches, including those based on the CRISPR-Cas9 system,
could have potential off-targets effects,27 we carried out a BLAST
analysis to predict potential off-targets, and we experimentally proved
that miniSINEUP-GDNF showed no effects on these mRNAs.
We have also demonstrated that in vivo expression of miniSINEUP-
GDNF RNA using an AAV9 is able to alter significantly the DA sys-
tem’s functions. In the striatum, we noted an increase in DA release
using in vivo microdialysis after amphetamine infusion or potassium
depolarization. Mice were also more sensitive to the locomotor effects
induced by the systemic administration of amphetamine. Strikingly,
DA storage pools were increased in striatal terminals by about
2-fold. It remains to be determined whether it is due to an increase
in DA content in the surviving terminals or in the number of DA ter-
minals in the striatum.side effects caused by the ectopic GDNF overexpression were measured, the
decrease in body weight (G) and the decrease in food intake (H). Mice injected with
AAV9-miniSINEUP-GDNF did not show any side effect (n = 9 for CTRL and 10 for
miniSINEUP-GDNF). Data represent means ± SEM. *p < 0.05, **p < 0.01, ***p <
0.001. Unpaired t test with Welch’s correction or repeated-measured ANOVA with
Newman-Keuls test (C and D) was used.
Figure 4. miniSINEUP-GDNF RNA Rescues
Neurodegeneration and Motor Phenotype in a PD
Neurochemical PD Mouse Model
(A) Scheme representing the experimental protocol
used for the assessment of the neuroprotective effect of
miniSINEUP-GDNF. AAV9 expressing miniSINEUP-GDNF
was injected 4 weeks before the lesion, then 6, 7, and
8 weeks after the lesion behavioral tests were performed to
verify the locomotor performance of mice. (B) Striatal lesion
after 6-OHDA infusion was measured by TH quantification
bywesternblot.Lesionedanimals revealedadecrease inTH
levels of approximately 50% (n = 5). (C) The severity of the
lesion was measured by the counting of the ipsilateral ro-
tations of the lesioned mice. Both spontaneous rotations
and the amphetamine-induced rotations were scored. For
spontaneous rotations, videos were recorded for 15 min,
while, for amphetamine-induced rotations, videos were re-
corded for 45min (n = 9/group). (D) To assess the severity of
the lesion, the cylinder test was carried out, where animals
were scored for the contralateral forepaw usage. Ipsilateral
touches were also counted (n = 9/group). (E) TH immuno-
reactivity of the striatum was evaluated by immunohisto-
chemistry inmice injectedwithAAV9-miniSINEUP-GDNF or
CTRL virus. Representative images of the striatum of min-
iSINEUP and CTRL animals are shown (upper panel).
Quantification of the TH immunoreactivitywas calculated for
all animals (lower panel) (n = 9/group). (F) TH-positive neu-
rons of the SNpc were evaluated by immunohistochemistry
in mice injected with AAV9-miniSINEUP-GDNF or CTRL
virus. Representative images of the SNpc of miniSINEUP
and CTRL animals are shown (upper panel). Quantification
of the TH-positive neurons was calculated for all animals
(lower panel) (n = 9/group). Data represent means ± SEM.
*p < 0.05, **p < 0.01, ***p < 0.001. Unpaired t test with
Welch’s correction was used.
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GDNF ectopic overexpression, such as decreases in body weight and
food intake. This is in line with our hypothesis that a moderate induc-
tion of GDNF expression in the correct cells, as mediated by SINEUP
RNA activity, could be beneficial as a standard gene therapy approach
but with less side effects. It should be noted that a more comprehen-
sive study on the consequences of the ectopic expression of SINEUP-
GDNF in other brain areas, including SNpc, will provide additional
information on this important issue.MolecMore importantly,miniSINEUP-GDNF was able
to ameliorate PD symptoms in the 6-OHDA PD
mouse model. We used two behavioral assays
widely used to assess the motor performance in
this PD mouse model, the cylinder test and the
rotational behavior. Mice injected with AAV9
expressing miniSINEUP-GDNF showed an
improvement in the usage of the contralateral
forepaw and significantly decreased the ipsilat-
eral rotations. These data demonstrated an
improvement in the motor behavior, the core
symptomatology of PD. By analyzing TH immu-noreactivity in the striatum and by counting DA neurons in the SNpc,
we also demonstrated that miniSINEUP-GDNF could decrease DA
loss induced by the 6-OHDA toxin infusion.
A limitation of this study is that there could be a difference in efficacy
and in off-targeting of this approach between PD rodent models and
humans. Studies in higher species such as non-human primates are,
therefore, needed to validate SINEUP efficacy in vivo. Furthermore,
it is well known that single PD mouse models are not reflecting theular Therapy Vol. 27 No 12 December 2019 7
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chemical intoxication, miniSINEUP-GDNF should be tested in other
PD animal models, including those based on alpha-synuclein
dysfunction. Importantly, while in this study RNA was expressed
before lesioning the striatum (neuroprotection), for a clinical perspec-
tive, miniSINEUP-GDNF activity should be evaluated when the brain
is lesioned before the delivery of the neurorestorative agent. There are
other technologies that can increase the endogenous expression of
selected genes, for example, zinc-finger-based artificial transcription
factors28 and CRISPR-based activation system (CRISPRa).29 Both
methods rely on the ability to stimulate transcription of a selected
gene by activating its promoter. Potential advantages of SINEUPs
over these technologies comprise SINEUPs work only when the target
mRNA is expressed and the induction is within physiological levels.
There are several examples in the literature of long-term expression of
transgenes in the human brain with AAV vectors.30,31 An alternative
strategy should be based on SINEUPs delivered as chemically synthe-
sized nucleic acids by, i.e., intrathecal injection. In this context, we are
focusing our efforts in decreasing the length of an active SINEUP.
While the original AS Uchl1 RNA was larger than 1 kb, a miniSI-
NEUP is around 250 nt long. A recent study of the structure of the
invSINEB2 element acting as the ED in AS Uchl1 has shown the
importance of Stem Loop 1 for SINEUP activity, prompting the syn-
thesis of shorter active ED variants.32
In summary, our study has demonstrated that SINEUPs are an inno-
vative technology to selectively increase the expression of target
mRNAs in vivo in a physiological and specific manner, representing
a new platform for gene therapy of neurodegenerative diseases.
MATERIALS AND METHODS
Construct
miniSINEUP-GDNFwas generated by using the SINEUP-DJ1 as back-
bone.16 BDs were designed in antisense orientation to the twomost ex-
pressed isoforms targeting the first AUG, with a long (40/+4) and a
short (14/+4) overlapping region. Oligonucleotides were annealed
and cloned into recipient pCS2 plasmid. For doxocycline experiments,
miniSINEUP-GDNF was cloned into a pLVX-TetOn-puro vector.
AAV-miniSINEUP-GDNF was generated modifying an existing
pAAV-CAG-EGFP vector (Addgene, 28014) by inserting between
the intron and the GFP a sequence coding for the miniSINEUP-
GDNF, a polyA signal, and a PGK promoter. This modification led
us to have the miniSINEUP-GDNF expressed by the CAG promoter
and the GFP expressed under the PGK promoter.
Cell Lines and Transfection
Neuro2a and C8-D1A astrocyte type I clone were obtained from
ATCC (Cat. No. CCL-131 and CRL-2541) and maintained in culture
with DMEM (Gibco by Life Technologies, Cat. No. 41090-028) supple-
mented with 10% fetal bovine serum and 1% antibiotics (penicillin/
streptomycin). Neuro2a and C8-D1A cells were plated in 6-well plates
the day before transfection at 60% confluency (4 105 cells/well) and
transfected with 1 mg SINEUPs encoding plasmids using Lipofect-8 Molecular Therapy Vol. 27 No 12 December 2019amine 2000 (Invitrogen by Life Technologies, Cat. No. 11668019),
following the manufacturer’s instructions. Cells were collected 48 h
after transfection. RNA and protein were obtained from the same
transfection in each replica. For doxocycline induction experiments,
Neuro2a was transfected with the pLVX-TetOn-puro vector express-
ing the miniSINEUP-GDNF and after 24 h doxocycline was added to
the medium. At 24 h after doxocycline, cells were harvested and
RNA and proteins were extracted. For the quantification of the
GDNF in the medium, a kit from Abcam (ab171178) was used accord-
ing to the manufacturer’s instructions.
RNA Extraction and qRT-PCR
Total RNA was extracted from cell pellets using TRIzol Reagent
(Thermo Fisher Scientific, Cat. No. 15596026) and following the
manufacturer’s instructions. RNA samples were subjected to DNase
(Sigma-Aldrich, Cat. No. AMPD1) treatment to avoid plasmid
DNA contamination. A total of 1 mg RNA was subjected to retrotran-
scription using iScriptcDNA Synthesis Kit (Bio-Rad, Cat. No.
1708890), according to the manufacturer’s instructions. qRT-PCR
was carried out using SYBR green fluorescent dye (SsoAdvanced Uni-
versal SYBR Green Supermix, Bio-Rad, Cat. No. 1725271) and an
CFX96 Real time PCR System (Bio-Rad). The reactions were per-
formed on diluted cDNA (1:8). Mouse glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) was used as the normalizing control in
all qRT-PCR experiments. The amplified transcripts were quantified
using the comparative Ct method, and the differences in gene expres-
sion were presented as normalized fold expression with the DDCt
method.
Western Blot
Centrifuged cells or striatum from mice were lysed in radioimmuno-
precipitation assay (RIPA) buffer with the addition of protease inhib-
itor cocktail (Sigma-Aldrich, Cat. No. P83490) buffer, briefly soni-
cated, and boiled for 5 min at 95C. 30 mg protein extracts were
resolved by 4%–12% SDS-PAGE gels and transferred to 0.2 mMnitro-
cellulose membrane (Amersham, Cat. No. GEH10600001) for 2 h at
35 V. Membranes were blocked with 5% non-fat dry milk in PBS/
0.1% Tween 20 and incubated with the following indicated primary
and secondary antibodies: anti-b-actin 1:20,000 (Sigma, Cat. No.
A2066), anti-GDNF 1:500 (Santa Cruz Biotechnology, Cat. No. sc-
328), anti-TH 1:1,000 (Millipore, Cat. No. AB152), anti-DAD1
1:1,000 (Novus Biologicals, Cat. No. NB600-669), anti-LRRC14
1:1,000 (Novus Biologicals, Cat. No. NBP1-80049), and anti-CBX4
1:500 (Santa Cruz Biotechnology, Cat. No. sc-517216). The antibody
against GDNF detects the mature form of GDNF, with an apparent
molecular weight of approximately 17 kDa. Proteins of interest
were visualized with the Amersham ECL Detection Reagents (GE
Healthcare by Sigma, Cat. No. RPN2105). Western blotting images
were acquired with Image Quant LAS 4000mini system, and band in-
tensity was calculated using Image Quant TL software.
Stereotaxic AAV9 and 6-OHDA Injection
The animals were anesthetized by a mixture of isoflurane/oxygen
(1.5% of isoflurane during anesthesia with 1 L/min oxygen) and
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CA, USA) with mouse adaptor and lateral ear bars. The skin on the
skull was cut and one hole was made on the same side by a surgical
drill. AAV9-SINEUP (titer 7.0  1012 vg/mL) or AAV9-CTRL (titer
7.0 1012 vg/mL) was injected 1 month before the lesion in order to
get the expression of the transgene. 1 mL virus was injected in the
right striatum at these cooordinates: anteroposterior (AP) 0.5,
dorsoventral (DV) 3.0, and lateral (L) 2.0. The virus was injected
using a glass pipette and the rate of infusion was of 1 mL/15 min. Af-
ter the infusion, the pipette was maintained for another 5 min in the
same position and then retracted slowly. At 4 weeks after the virus
injection, all the animals received a stereotaxic injection of
6-OHDA or PBS at the same coordinates. 6-OHDA was dissolved
in ascorbate-CNS Fluid 0.02% at a concentration of 4 mg/mL and
the volume administered was 2 mL. All the animals received a
desipramine 35 mg/kg injection (intraperitoneally [i.p.], dissolved
in saline) to protect the noradrenergic innervations into the stria-
tum. Sham-lesioned mice were injected with 0.02% ascorbate-saline
devoid of 6-OHDA.
Behavioral Testing
All procedures involving animals and their care were carried out in
accordance with the guidelines established by the European Commu-
nity Council (Directive 2010/63/EU of September 22, 2010) and were
approved by the Italian Ministry of Health (DL 116/92 and DL 111/
94-B).
Locomotor Activity
To measure spontaneous locomotor activity, WT mice injected with
AAV9 were placed in the locomotor activity chambers (Omnitech
Digiscan, Accuscan Instruments, Columbus, PO, USA) for 60 min,
and total distance traveled was measured by analyzing infrared
beam interruptions. For amphetamine experiments, mice were
habituated for 30 min in the apparatus and then injected i.p. with
2.5 mg/kg amphetamine (Sigma-Aldrich), and the distance traveled
was measured for another 60 min.
Cylinder Test
During this test, animals were allowed to freely move in a clear glass
cylinder for 5 min. A video camera was placed above the cylinder in
order to see all the paw placements during the recording. An observer
blinded to the animal treatment group viewed the recording and
counted all the forepaw touches to the cylinder. The data were ex-
pressed as the percentage of contralateral touches.
Rotations
Spontaneous rotations were recorded 7 weeks after the lesion, while
amphetamine-induced rotations were recorded 8 weeks after the
lesion. Animals were placed in a glass cylinder 20 cm in diameter,
and the rotational behavior was video recorded. For spontaneous
rotation, mice were monitored for 15 min. For amphetamine-induced
rotation, mice were injected i.p. with amphetamine at the dose of
2.5 mg/kg, and then animals were monitored for 45 min. Rotations
were expressed as full 360 ipsilateral rotations.Perfusion and Tissue Processing
Mice were deeply anesthetized with urethane (50 mg/kg, 10 mL/kg
body weight, i.p., Sigma-Aldrich) and perfusion fixed by 10 mL
0.1M phosphate buffer (pH 7.4) followed by 20mL 4% formaldehyde.
Brains were rapidly extracted and post-fixed in the same solution for
12 h at 4C, and then cryoprotected in 30% sucrose in 0.1 M phos-
phate buffer (pH 7.4) for 48 h at 4C. Sections were cut at 40 mm
in the coronal plane on a freezing microtome from the front of the
striatum to the end of the retrorubral field.
Immunohistochemistry for TH
The sections were rinsed three times in 0.1M PBS (pH 7.6), contained
0.1% Triton X-100 between each incubation period. All sections were
quenched with 3%H2O2/10% for 10 min, followed by several changes
of buffer. As a blocking step, sections were then incubated in 7%
normal goat serum and 0.1% Triton X-100 for 2 h at room tempera-
ture. This was followed by incubation in primary antibody diluted in
3% normal goat serum and 0.1% Triton X-100 at 4C for 24 h. The
antibody used was an anti-TH diluted 1:500 (AB-152, Millipore). Af-
ter incubation with the primary antibody, sections were rinsed and
then incubated for 2 h at room temperature with biotinylated second-
ary antibodies (anti-rabbit 1:1,000; Thermo Scientific) in the same
buffer solution. The reaction was visualized with avidin-biotin-perox-
idase complex (ABC-Elite, Vector Laboratories), using 3,3-diamino-
benzidine as a chromogen. Sections were mounted on super-frost ul-
tra plus slides (Thermo Scientific), dehydrated in ascending alcohol
concentrations, cleared in xylene, and coverslipped in dibutyl phtha-
late polystyrene xylen (DPX) mounting medium. All sections were
analyzed in the same experiment to keep staining conditions
constant.
SNpc Cell Counts
The number of TH-positive cells was determined by counting every
fourth 40-mm section, as previously described.33 The delimitation be-
tween the ventral tegmental area and the SN was determined by using
themedial terminal nucleus of the accessory optic tract as a landmark.
The unlesioned side was used as a control for the percentage of re-
maining neurons in each group.
Striatal Fiber TH Densitometry
The optical densities of the TH immunoreactive fibers in the striatum
were measured using the NIH ImageJ program. For each animal the
optical density was measured at four rostocaudal levels over the whole
striatum. To estimate TH staining density, the optical density was
corrected for non-specific background density, as measured from
the corpus callosum in each section. Data were presented as the
average of the four rostrocaudal slice levels expressed as a percentage
of the intact side.
Statistical Analysis
In all experiments, the significance of differences between groups was
evaluated by Student’s t test, one-way ANOVA, or repeated-measures
ANOVA. p < 0.05 was considered significant. Quantitative data are
presented as mean ± SEM.Molecular Therapy Vol. 27 No 12 December 2019 9
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